- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Episode 8 - Changing the T2DM Treatment Paradigm
Peter Salgo, MD, notes that type 2 diabetes mellitus (T2DM) is associated with multiple metabolic defects. Traditional agents (eg, metformin, TZDs, and sulfonylureas) target insulin production and sensitivity. Agents with novel mechanisms of action are now available for T2DM, including agents that target the incretin system and agents that affect renal glucose handling. Characteristics of the various drugs may make them more suitable for individual patients.
Kari Uusinarkaus, MD, FAAFP, FNLA, comments that glucagon-like peptide agents are a good adjunct to metformin treatment because they reduce weight in patients while improving glycated hemoglobin levels. For this reason, this treatment option is often preferred by patients.
Yehuda Handelsman, MD, FACP, FACE, FNLA, describes safety considerations regarding the newer agents, including increases in risk for acute pancreatitis and heart disease, and use in patients with renal impairment.
Jeffrey D. Dunn, PharmD, MBA, discusses the costs of emerging diabetes treatment options. Dr Dunn and Maria Lopes, MD, MS, stress the importance of individualizing treatment and taking into account both efficacy and cost when treating patients with T2DM.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More
Makers of medical tests will have about 4 years to show the FDA that their new offerings deliver accurate results; after previously decreasing for 27 years, US tuberculosis (TB) cases increased every year since 2020; a US district judge rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to the Medicare drug price negotiation program.
Read More
